IntrinsicIntrinsic
← Scroll for more →

Recent Updates — NIMU

November 4, 2026View Source ↗

Non-Invasive Monitoring Systems extends the outside closing and termination dates for its merger with Gravitics from October 30, 2026, to November 30, 2026. The company also extended the maturity of four affiliate promissory notes totaling $300,000 held by Dr. Jane Hsiao and Frost Gamma Investments Trust to November 30, 2026. Additionally, Amendment No. 2 to a $809,705.75 convertible note with Defender Opportunity LLC extends the automatic conversion date to November 30, 2026 in exchange for a $25,000 fee. The company develops non-invasive medical monitoring technologies.

October 19, 2026View Source ↗

Non-Invasive Monitoring Systems, Inc. entered into a fourth amendment to its Agreement and Plan of Merger and Reorganization with Gravitics, Inc., modifying the definition of "Public Offering" to require gross proceeds currently expected to be $50 million, but in no event less than $40 million. All other terms remain unchanged. The company develops non-invasive medical monitoring technologies.

October 5, 2026View Source ↗

Non-Invasive Monitoring Systems amended its merger agreement with Gravitics, extending the outside closing date to October 30, 2026. The amendment increases the target size of the related underwritten public offering from $40 million to $125 million and removes certain closing conditions, including a cap on dissenting shares. Additionally, the company amended a convertible note held by Defender Opportunity LLC, extending its conversion deadline to October 30 in exchange for a $25,000 fee. The company develops non-invasive medical monitoring technology.

August 17, 2026View Source ↗

Non-Invasive Monitoring Systems, Inc. entered into a second amendment to its Agreement and Plan of Merger with Gravitics, Inc., modifying the post-merger ownership structure. Following the merger, Gravitics stockholders will own approximately 96.5% of the combined company, while Non-Invasive Monitoring Systems' stockholders will retain approximately 3.5%. This transaction represents a significant change in control and equity distribution for the company, which operates in the medical technology industry developing non-invasive diagnostic systems.